Adalat Logo

Bayer HealthCare

     

A Coronary Disease Trial Investigating Outcome with Nifedipine GITS

A Coronary Disease Trial Investigating Outcome with Nifedipine GITS (ACTION) was a randomised, double-blind, placebo-controlled trial that included 7,665 patients and examined whether Adalat® (nifedipine GITS) has beneficial effects on clinical outcomes in patients with chronic stable angina. ACTION aims to provide information on how the effects of Adalat® in addition to blood-pressure control – such as slowing disease progression and improving endothelial function – translate into long-term clinical benefits. The trial results were released at the European Society of Cardiology (ESC) Congress 2004 in Munich, Germany, and have since been published in The Lancet (2004).1

Hypertensive Subgroup Analysis

Following publication of the primary ACTION results, the first subgroup analysis was published in June 2005. These results clearly demonstrate the benefits of Adalat® therapy in patients with symptomatic stable angina and hypertension, setting new standards for optimising therapy for these patients.2 Read more...

Adalat® ACTION Expert Meeting

Learn more about the Adalat® ACTION Expert Meeting held in Portugal in November 2003, including a series of expert interviews. 
Click here.

 

ACTION Primary Endpoints

The combined primary endpoint of ACTION includes death, acute myocardial infarction, stroke, emergency coronary angiography for refractory angina, and severe peripheral vascular disease.

For more detailed information on ACTION, please visit the ACTION website.

1. Poole-Wilson P, et al. Lancet 2004;364:849–57.
2. Lubsen J, et al. J Hypertension 2005; 23:641–8.